EU Critical Medicines Act and China Supply Risk
Decision brief
Answer first · skim in under a minute
The European Union is tightening industrial-policy tools around critical medicines as lawmakers advance the Critical Medicines Act. The March 2025 Commission proposal and May 2026 provisional political agreement aim to reduce dependency on non-EU active pharmaceutical ingredient suppliers, including concentrated capacity in China and India.
The European Union is tightening industrial-policy tools around critical medicines as lawmakers advance the Critical Medicines Act. The March 2025 Commission proposal and May 2026 provisional political agreement aim to reduce dependency on non-EU active pharmaceutical ingredient suppliers, including concentrated capacity in China and India.
Contents10 sections
Key Takeaways
- The Commission proposed the Critical Medicines Act in March 2025 to strengthen EU availability and production of critical medicines.
- Commission analysis cites roughly 75% of certified API production sites outside the EU, notably in India and China, with no EU production for about 21% of APIs studied.
- A provisional Parliament-Council agreement on 12 May 2026 backs strategic projects and procurement rules that can reward EU manufacturing share.
- The Act complements—not replaces—trade-defense instruments and the broader EU pharma legislation reform.
What is the Critical Medicines Act trying to fix?
The Commission’s Critical Medicines Act page frames the regulation as a way to improve availability, supply, and production of critical medicines inside the EU, plus access to medicines of common interest such as some rare-disease therapies.
Key features include designating Strategic Projects with faster permitting and funding access, using public procurement to reward supply-chain resilience, enabling collaborative procurement across member states, and exploring international partnerships to diversify suppliers.
How exposed is Europe to Asian API manufacturing?
The Commission staff working document supporting the proposal (SWD(2025) 263) reports heavy dependence on non-EU API manufacturers. About 75% of API production sites in the EDQM certification analysis sat outside the EU, notably in India and China.
For roughly 21% of APIs examined in the exploratory study, there was no EU production at all. That concentration is the industrial-policy problem the Act tries to price into procurement and investment incentives.
What changed with the May 2026 provisional deal?
Parliament and Council negotiators reached a provisional agreement on 12 May 2026. Public summaries emphasize strategic projects for EU manufacturing capacity and procurement rules that can reward the share of medicines and APIs produced in the EU when supply is highly dependent on third countries.
Orphan medicines can benefit from strategic-project and collaborative-procurement pathways under the political deal descriptions. Formal entry into force still requires approval by both institutions after legal-linguistic revision.
Is this a tariff war or an industrial-policy shift?
The Act is primarily an availability and manufacturing-capacity instrument, not a classic anti-dumping tariff schedule. It sits beside separate EU trade-defense tools that can address dumped or subsidized imports when legal criteria are met.
For China-facing API and finished-dose suppliers, the practical impact runs through tender scoring, dual-sourcing requirements, and eligibility for strategic-project support—not solely through headline duties.
What should BD and supply-chain leaders do now?
Map which SKUs sit on the Union list of critical medicines and where their APIs are made. Dual-source dossiers should document EU or likeminded-country capacity even if current COGS favor a single Asian site.
- Model tender scores if EU manufacturing share becomes a weighted criterion.
- Track Strategic Project designation criteria as guidance firms land.
- Separate CMA planning from routine CHMP label catalysts.
What remains unproven?
Provisional political agreement is not final law. Implementing acts, state-aid guidance, and national procurement practice will determine whether EU capacity actually gets built.
Dependency statistics describe structural risk; they do not prove any single Chinese manufacturer will lose a specific tender in 2026. Watch Commission decision texts and first Strategic Project awards for hard evidence.
Related NovaPharma coverage
Frequently Asked Questions
When was the Critical Medicines Act proposed?
The European Commission proposed the Critical Medicines Act in March 2025.
What dependency figures does the Commission cite?
Supporting analysis reports about 75% of certified API production sites outside the EU, notably in India and China, and no EU production for about 21% of APIs studied.
Has the Act become law?
A provisional Parliament-Council agreement was reached on 12 May 2026; final adoption and entry into force were still pending after that deal.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
